ArticlePloS one2024

Characteristics of patients with longer treatment period of lenvatinib for unresectable hepatocellular carcinoma: A post-hoc analysis of post-marketing surveillance study in Japan.

Tatsuya Yamashita et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.